Itunu Owoyemi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Itunu Owoyemi has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Nelson Leung
Division of Hematology, Mayo Clinic, Rochester, MN
2 shared publications Aaron Byers
Internal Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA
1 shared publication- Aaron R. Mangold
Department of Dermatology, Mayo Clinic, Scottsdale, USA
1 shared publication - Abbas Shahmohammadi1 shared publication
- Aditi Gupta
Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
1 shared publication - Akhil Sharma
King George's Medical University, Lucknow, Uttar Pradesh, 226003, India
1 shared publication
Latest Publications
- 2 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (8) , 1302-1303
A Beacon of Hope
- 2 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (8) , 1302-1303
A Beacon of Hope
- Open Access
- 25 March 2026
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 22
Liver transplantation for valproic acid-induced acute liver failure in POLG mutation-related mitochondrial disease with cardiac and neurological involvement
- 25 March 2026
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 22
Open AccessLiver transplantation for valproic acid-induced acute liver failure in POLG mutation-related mitochondrial disease with cardiac and neurological involvement
- 25 May 2022
- Published by Elsevier in Journal of the National Medical Association
- Vol. 114 (3) , S1-S2
Frontiers in chronic kidney disease management
- 25 May 2022
- Published by Elsevier in Journal of the National Medical Association
- Vol. 114 (3) , S1-S2
Frontiers in chronic kidney disease management
- 29 April 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15 (4) , e248668
Chronic inflammation and calciphylaxis
Calciphylaxis also known as calcific uraemic arteriolopathy is a rare condition mostly seen in patients with end-stage kidney disease. We report a case of a simultaneous-kidney-pancreas transplant patient with functioning grafts developing biopsy-proven calciphylaxis in the setting of chronic inflammation. Despite several modalities of management, the patient developed progression of her disease leading to multiple amputations. This case illustrates chronic inflammation driven by persistent infection as a probable contributing factor to the development and progression of calciphylaxis in a simultaneous kidney-pancreas recipient. Calciphylaxis should be considered in the differential for a painful, non-healing ulcer even in the absence of common risk factors.
- 29 April 2022
- Published by BMJ in BMJ Case Reports
- Vol. 15 (4) , e248668
Chronic inflammation and calciphylaxis
Calciphylaxis also known as calcific uraemic arteriolopathy is a rare condition mostly seen in patients with end-stage kidney disease. We report a case of a simultaneous-kidney-pancreas transplant patient with functioning grafts developing biopsy-proven calciphylaxis in the setting of chronic inflammation. Despite several modalities of management, the patient developed progression of her disease leading to multiple amputations. This case illustrates chronic inflammation driven by persistent infection as a probable contributing factor to the development and progression of calciphylaxis in a simultaneous kidney-pancreas recipient. Calciphylaxis should be considered in the differential for a painful, non-healing ulcer even in the absence of common risk factors.
- Open Access
- 30 July 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (12) , 4068-4072
Posttransplant proteinuria due to Apolipoprotein E2 deposition in a kidney allograft
- 30 July 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (12) , 4068-4072
Open AccessPosttransplant proteinuria due to Apolipoprotein E2 deposition in a kidney allograft
- Open Access
- 8 June 2021
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 7 (7) , e706
Impact of Subclinical and Clinical Kidney Allograft Rejection Within 1 Year Posttransplantation Among Compatible Transplant With Steroid Withdrawal Protocol
Background.: Early acute kidney rejection remains an important clinical issue. Methods.: The current study included 552 recipients who had 1–2 surveillance or indication biopsy within the 1 y posttransplant. We evaluated the impact of type of allograft inflammation on allograft outcome. They were divided into 5 groups: no inflammation (NI: 95), subclinical inflammation (SCI: 244), subclinical T cell–mediated rejection (TCMR) (SC-TCMR: 110), clinical TCMR (C-TCMR: 83), and antibody-mediated rejection (AMR: 20). Estimated glomerular filtration rate (eGFR) over time using linear mixed model, cumulative chronic allograft scores/interstitial fibrosis and tubular atrophy (IFTA) ≥2 at 12 mo, and survival estimates were compared between groups. Results.: The common types of rejections were C-TCMR (15%), SC-TCMR (19.9%), and AMR (3.6%) of patients. Eighteen of 20 patients with AMR had mixed rejection with TCMR. Key findings were as follows: (i) posttransplant renal function: eGFR was lower for patients with C-TCMR and AMR (P < 0.0001) compared with NI, SCI, and SC-TCMR groups. There was an increase in delta-creatinine from 3 to 12 mo and cumulative allograft chronicity scores at 12 mo (P < 0.001) according to the type of allograft inflammation. (ii) Allograft histology: the odds of IFTA ≥2 was higher for SC-TCMR (3.7 [1.3-10.4]; P = 0.04) but was not significant for C-TCMR (3.1 [1.0-9.4]; P = 0.26), and AMR (2.5 [0.5-12.8]; P = 0.84) compared with NI group, and (iii) graft loss: C-TCMR accounted for the largest number of graft losses and impending graft losses on long-term follow-up. Graft loss among patient with AMR was numerically higher but was not statistically significant. Conclusions.: The type of kidney allograft inflammation predicted posttransplant eGFR, cumulative chronic allograft score/IFTA ≥2 at 12 mo, and graft loss.
- 8 June 2021
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 7 (7) , e706
Open AccessImpact of Subclinical and Clinical Kidney Allograft Rejection Within 1 Year Posttransplantation Among Compatible Transplant With Steroid Withdrawal Protocol
Background.: Early acute kidney rejection remains an important clinical issue. Methods.: The current study included 552 recipients who had 1–2 surveillance or indication biopsy within the 1 y posttransplant. We evaluated the impact of type of allograft inflammation on allograft outcome. They were divided into 5 groups: no inflammation (NI: 95), subclinical inflammation (SCI: 244), subclinical T cell–mediated rejection (TCMR) (SC-TCMR: 110), clinical TCMR (C-TCMR: 83), and antibody-mediated rejection (AMR: 20). Estimated glomerular filtration rate (eGFR) over time using linear mixed model, cumulative chronic allograft scores/interstitial fibrosis and tubular atrophy (IFTA) ≥2 at 12 mo, and survival estimates were compared between groups. Results.: The common types of rejections were C-TCMR (15%), SC-TCMR (19.9%), and AMR (3.6%) of patients. Eighteen of 20 patients with AMR had mixed rejection with TCMR. Key findings were as follows: (i) posttransplant renal function: eGFR was lower for patients with C-TCMR and AMR (P < 0.0001) compared with NI, SCI, and SC-TCMR groups. There was an increase in delta-creatinine from 3 to 12 mo and cumulative allograft chronicity scores at 12 mo (P < 0.001) according to the type of allograft inflammation. (ii) Allograft histology: the odds of IFTA ≥2 was higher for SC-TCMR (3.7 [1.3-10.4]; P = 0.04) but was not significant for C-TCMR (3.1 [1.0-9.4]; P = 0.26), and AMR (2.5 [0.5-12.8]; P = 0.84) compared with NI group, and (iii) graft loss: C-TCMR accounted for the largest number of graft losses and impending graft losses on long-term follow-up. Graft loss among patient with AMR was numerically higher but was not statistically significant. Conclusions.: The type of kidney allograft inflammation predicted posttransplant eGFR, cumulative chronic allograft score/IFTA ≥2 at 12 mo, and graft loss.
- Open Access
- 1 March 2021
- Published by Elsevier in Kidney Medicine
- Vol. 3 (2) , 303-306
Kidney Injury in Multiple Myeloma: A Kidney Biopsy Teaching Case
- 1 March 2021
- Published by Elsevier in Kidney Medicine
- Vol. 3 (2) , 303-306
Open AccessKidney Injury in Multiple Myeloma: A Kidney Biopsy Teaching Case
Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single‐center analysis
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but to the authors' knowledge, limited data exist regarding the safety and efficacy of these agents in transplant recipients. Herein, the authors have reported their experience with 17 patients who were treated with ICIs for metastatic malignancies after undergoing solid organ transplantation.Methods: Data were abstracted for solid organ transplant recipients who received ICIs for the treatment of malignancy between January 1, 2016, and September 30, 2019. The authors identified 7 kidney, 8 liver, and 2 heart transplant recipients. Outcomes of interest were adverse drug reactions, cancer progression, and patient survival.Results: The most common malignancies treated with ICIs were metastatic squamous cell carcinoma (5 patients; 29%) and hepatocellular carcinoma (5 patients; 29%), which were noted exclusively among liver transplant recipients. The median duration on ICIs was 1.7 months (interquartile range, 0.4‐7.6 months). Five patients (29%) developed adverse reactions, including 4 patients (24%) with immune‐related adverse events(irAEs), 3 patients (18%) with acute allograft rejections, 1 patient (6%) with autoimmune colitis, and 1 patient (6%) with ICI‐induced cardiotoxicity (the patient was a heart transplant recipient). The cumulative incidence of cancer progression was 50% and 69%, respectively, at 6 months and 12 months. Eleven patients (65%) died over the median follow‐up period of 4.6 months (interquartile range, 1.5‐13.2 months) from the time of ICI initiation, with cancer progression being the most common cause of death.Conclusions: ICIs can be used as individualized therapy in selected patients who have undergone solid organ transplantation but more studies are needed to determine how best to use these agents to improve outcomes further.
Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single‐center analysis
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but to the authors' knowledge, limited data exist regarding the safety and efficacy of these agents in transplant recipients. Herein, the authors have reported their experience with 17 patients who were treated with ICIs for metastatic malignancies after undergoing solid organ transplantation.Methods: Data were abstracted for solid organ transplant recipients who received ICIs for the treatment of malignancy between January 1, 2016, and September 30, 2019. The authors identified 7 kidney, 8 liver, and 2 heart transplant recipients. Outcomes of interest were adverse drug reactions, cancer progression, and patient survival.Results: The most common malignancies treated with ICIs were metastatic squamous cell carcinoma (5 patients; 29%) and hepatocellular carcinoma (5 patients; 29%), which were noted exclusively among liver transplant recipients. The median duration on ICIs was 1.7 months (interquartile range, 0.4‐7.6 months). Five patients (29%) developed adverse reactions, including 4 patients (24%) with immune‐related adverse events(irAEs), 3 patients (18%) with acute allograft rejections, 1 patient (6%) with autoimmune colitis, and 1 patient (6%) with ICI‐induced cardiotoxicity (the patient was a heart transplant recipient). The cumulative incidence of cancer progression was 50% and 69%, respectively, at 6 months and 12 months. Eleven patients (65%) died over the median follow‐up period of 4.6 months (interquartile range, 1.5‐13.2 months) from the time of ICI initiation, with cancer progression being the most common cause of death.Conclusions: ICIs can be used as individualized therapy in selected patients who have undergone solid organ transplantation but more studies are needed to determine how best to use these agents to improve outcomes further.
- Open Access
- 11 February 2020
- Published by SAGE Publications in Journal of Onco-Nephrology
- Vol. 4 (1-2) , 18-21
Pro-kidney transplantation should be considered in patients with multiple myeloma
Multiple myeloma is the most frequent malignant monoclonal gammopathy and the second most common hematological malignancy after non-Hodgkin lymphoma. There continues to be evolving therapies in the treatment which has significantly changed progression-free and overall survival of the patients. Increasingly, evidence shows that multiple myeloma no longer portends poor and lethal prognosis. With the advances in treatment of multiple myeloma and improved survival as seen in several studies, perhaps more attention should focus on kidney transplantation in these individuals given their suboptimal outcomes on dialysis. We would like to propose that a diagnosis of multiple myeloma not be considered as an absolute contraindication for kidney transplantation. Rather, a careful consideration of kidney transplantation is appropriate for a subset of patients with multiple myeloma and end-stage kidney disease. The candidacy of these patients should be reviewed by a multidisciplinary team comprising experts in hematology, kidney transplantation, and key stakeholders (including laboratory medicine, renal pathologists, and pharmacists) to allow appropriate risk stratification, prognostication for a successful and safe kidney transplantation.
- 11 February 2020
- Published by SAGE Publications in Journal of Onco-Nephrology
- Vol. 4 (1-2) , 18-21
Open AccessPro-kidney transplantation should be considered in patients with multiple myeloma
Multiple myeloma is the most frequent malignant monoclonal gammopathy and the second most common hematological malignancy after non-Hodgkin lymphoma. There continues to be evolving therapies in the treatment which has significantly changed progression-free and overall survival of the patients. Increasingly, evidence shows that multiple myeloma no longer portends poor and lethal prognosis. With the advances in treatment of multiple myeloma and improved survival as seen in several studies, perhaps more attention should focus on kidney transplantation in these individuals given their suboptimal outcomes on dialysis. We would like to propose that a diagnosis of multiple myeloma not be considered as an absolute contraindication for kidney transplantation. Rather, a careful consideration of kidney transplantation is appropriate for a subset of patients with multiple myeloma and end-stage kidney disease. The candidacy of these patients should be reviewed by a multidisciplinary team comprising experts in hematology, kidney transplantation, and key stakeholders (including laboratory medicine, renal pathologists, and pharmacists) to allow appropriate risk stratification, prognostication for a successful and safe kidney transplantation.